Responses
Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
160 Circulating tumor DNA for measurable residual disease (MRD) detection in multiple myeloma patients undergoing CAR T-cell therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.